Biren Amin
Stock Analyst at Piper Sandler
(0.80)
# 3,794
Out of 4,880 analysts
59
Total ratings
26.92%
Success rate
-22.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $0.64 | +525.49% | 1 | Jun 26, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $70 → $36 | $17.71 | +103.27% | 8 | Jun 16, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $4.60 | +269.57% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.18 | +493.22% | 3 | May 14, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $46 → $63 | $42.78 | +47.27% | 2 | Apr 30, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $30.05 | +69.72% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $13.11 | +189.86% | 1 | Mar 31, 2025 | |
| ELEV Elevation Oncology | Downgrades: Neutral | $10 → $0.7 | $0.37 | +89.96% | 2 | Mar 21, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $34.60 | +119.65% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $2.58 | +365.12% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $26.67 | +166.22% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $4 | $4.20 | -4.76% | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.16 | +388.83% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $8.47 | +148.08% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $64.78 | +77.54% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $17.87 | +79.07% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $4.84 | -38.02% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.10 | +64.84% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.19 | +5,782.35% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.39 | +12,960.18% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $3.93 | +510.69% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.34 | +1,352.99% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $4.84 | +10,230.58% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.53 | +153.16% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $534.91 | +29.18% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $2.36 | +323.73% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $22.61 | +346.71% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $128.00 | -46.09% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $452.16 | -65.72% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.69 | +7,947.34% | 4 | Mar 6, 2017 |
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $0.64
Upside: +525.49%
Sarepta Therapeutics
Jun 16, 2025
Downgrades: Neutral
Price Target: $70 → $36
Current: $17.71
Upside: +103.27%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $4.60
Upside: +269.57%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.18
Upside: +493.22%
BridgeBio Pharma
Apr 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $42.78
Upside: +47.27%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $30.05
Upside: +69.72%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $13.11
Upside: +189.86%
Elevation Oncology
Mar 21, 2025
Downgrades: Neutral
Price Target: $10 → $0.7
Current: $0.37
Upside: +89.96%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $34.60
Upside: +119.65%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $2.58
Upside: +365.12%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $26.67
Upside: +166.22%
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.20
Upside: -4.76%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $7.16
Upside: +388.83%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $8.47
Upside: +148.08%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $64.78
Upside: +77.54%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $17.87
Upside: +79.07%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $4.84
Upside: -38.02%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $9.10
Upside: +64.84%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.19
Upside: +5,782.35%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.39
Upside: +12,960.18%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $3.93
Upside: +510.69%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.34
Upside: +1,352.99%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $4.84
Upside: +10,230.58%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $5.53
Upside: +153.16%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $534.91
Upside: +29.18%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $2.36
Upside: +323.73%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $22.61
Upside: +346.71%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $128.00
Upside: -46.09%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $452.16
Upside: -65.72%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.69
Upside: +7,947.34%